December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

221.11 +8.82 (+4.15%)
Streaming Delayed Price Updated: 1:19 PM EDT, Mar 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ligand Pharmaceuticals Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Ligand Pharmaceuticals Incorporated (LGND) Q3 2021 Earnings Call Transcript ↗
LGND earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Recap: Ligand Pharmaceuticals Q3 Earnings ↗
Ligand Pharmaceuticals (NASDAQ:LGND) reported its Q3 earnings results on Tuesday, November 9, 2021 at 04:01 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
News headline image
Ligand Reports Third Quarter 2021 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Antitrust Nod For Acceleron Deal In Germany, Austria, Announces... 
Via Benzinga
News headline image
Ligand to Report Third Quarter Financial Results on November 9, 2021
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More ↗
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out... 
Via Benzinga
News headline image
Ligand Outlicenses BEPro Tech To Develop Oral COVID-19 Antivirals ↗
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has signed a collaboration agreement with Double-Crane Pharmaceutical Co Ltd (CRDC). The agreement grants... 
Via Benzinga
News headline image
Ligand and CR Double-Crane Enter Collaboration Agreement to Develop an Oral COVID-19 Therapeutic Using Ligand’s BEPro Technology™
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Stock Shows Rising Price Performance ↗
A Relative Strength Rating upgrade for San Diego-based Ligand Pharmaceuticals stock shows improving technical performance. 
Via Investor's Business Daily
News headline image
Ligand Pharmaceuticals Stock Shows Market Leadership With Jump To 82 RS Rating ↗
Ligand Pharmaceuticals stock saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 71 to 82. 
Via Investor's Business Daily
News headline image
Why Digital Turbine's Stock Is Trading Higher Today ↗
Digital Turbine Inc (NASDAQ: APPS) is trading higher Tuesday after it was announced the company is set to join the S&P MidCap 400. Digital Turbine will replace ... 
Via Benzinga
Topics Stocks
News headline image
Digital Turbine Added To S&P MidCap 400 Index ↗
Media and mobile communications company Digital Turbine Inc (NASDAQ: 
Via Benzinga
Topics Stocks
News headline image
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
News headline image
Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
From Ligand Pharmaceuticals
Via Business Wire
News headline image
What To Know About Rand Paul Failing To Disclose Gilead Stock Purchase For 16 Months ↗
Stock transactions by members of the U.S. Congress and their spouses have been a hot topic over the last several years. A transaction disclosed late Wednesday is drawing heavy... 
Via Benzinga
News headline image
Ligand Pharmaceuticals Incorporated (LGND) Q2 2021 Earnings Call Transcript ↗
LGND earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
Ligand Reports Second Quarter 2021 Financial Results
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More ↗
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
News headline image
Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia chrysanthemi (recombinant)-rywn), Formerly JZP458
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand’s Partner Merck Receives FDA Approval for VAXNEUVANCE™ for the Prevention of Invasive Pneumococcal Disease in Adults Caused by 15 Serotypes
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
The Week Ahead In Biotech: Earnings Kickstart With J&J And Biogen, Albireo Awaits FDA Decisions, More IPOs ↗
Biotech stocks were down for a second week in a row, as they retreated along with the broader market amid macro concerns. Consumer price inflation data released during the week... 
Via Benzinga
News headline image
Ligand to Report Second Quarter Financial Results on July 29, 2021
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Ligand Pharmaceuticals Appoints Dr. Jennifer Cochran to its Board of Directors
From Ligand Pharmaceuticals Incorporated
Via Business Wire
News headline image
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates ↗
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive... 
Via Benzinga
News headline image
When Cap-Weighted Small-Cap Funds Own “Meme” Stocks ↗
I cannot say whether GameStop or the other meme stocks will get their businesses back on their feet. What I can say is that, if you are tracking various small-cap indexes, you just might own them, like... 
Via Talk Markets
News headline image
Ligand's Revenue Soars in Q1 Thanks to Gilead's COVID Drug ↗
The drugmaker is also looking for its highest sales ever in 2021 in large part because of remdesivir. 
Via The Motley Fool
News headline image
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.